CGON CG Oncology Inc.
QT39| Index | — | P/E | — | EPS (ttm) | -2.70 | Insider Own | 14.34% | Shs Outstand | 88.64M | Perf Week | 0.65% |
| Market Cap | 5.49B | Forward P/E | — | EPS next Y | -3.13 | Insider Trans | 2.60% | Shs Float | 68.28M | Perf Month | -8.04% |
| Enterprise Value | 4.47B | PEG | — | EPS next Q | -0.83 | Short Float | 13.00% | Perf Quarter | -13.22% | ||
| Income | -224.00M | P/S | — | EPS this Y | — | Short Ratio | 10.19 | Perf Half Y | -8.48% | ||
| Sales | 6.00M | P/B | 5.34 | EPS next Y | — | ROA | -20.67% | Short Interest | 8.87M | Perf YTD | 49.23% |
| Book/sh | 11.61 | P/C | 5.34 | EPS next 5Y | — | ROE | -25.20% | 52W High | 80.97 -21.64% | Perf Year | 45.89% |
| Cash/sh | 11.60 | P/FCF | — | EPS past 3/5Y | — | ROIC | -24.30% | 52W Low | 35.80 77.23% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | -82.69% | Volatility | 5.45% 4.27% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | -4056.18% | ATR (14) | 2.93 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 22.20 | Sales Y/Y TTM | — | Profit Margin | -3602.68% | RSI (14) | 41.29 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 22.22 | EPS Q/Q | -66.67% | SMA20 | -0.79% | Beta | 1.07 | Target Price | 86.50 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -10.30% | Rel Volume | 1.45 | Prev Close | 61.96 |
| Employees | 142 | LT Debt/Eq | 0.01 | Earnings | Nov 13 | SMA200 | -6.05% | Avg Volume | 883.12K | Price | 63.45 |
| IPO Date | Jan 25, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -35.51% 220.67% | Net Debt/EBITDA | — | Volume | 1,279,526 | Change | 2.40% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Truist Securities | Buy | $82 → $85 |
| Jul-29-26 | Reiterated | H.C. Wainwright | Buy | $75 → $100 |
| May-14-26 | Reiterated | Truist Securities | Buy | $75 → $82 |
| May-11-26 | Reiterated | Truist Securities | Buy | $75 → $82 |
| May-11-26 | Reiterated | Wedbush | Outperform | $70 → $80 |
| May-11-26 | Reiterated | RBC Capital | Outperform | $79 → $81 |
| Apr-27-26 | Reiterated | RBC Capital | Outperform | $73 → $79 |
| Mar-26-26 | Reiterated | UBS | $60 → $90 | |
| Feb-10-26 | Reiterated | Truist Securities | Buy | $66 → $75 |
| Jan-21-26 | Reiterated | RBC Capital | Outperform | $61 → $73 |
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 6 | 4 | 1 | 0 | — | — | |
| Cost of Goods Sold Incl. D&A | 12 | 5 | 82 | 46 | — | — | |
| Gross Profit | -6 | -1 | -81 | -46 | — | — | |
| Selling, General and Administrative Excl. Other | 91 | 74 | 34 | 10 | — | — | |
| Research and Development | 157 | 117 | 82 | 46 | — | — | |
| Other Operating Expense | 0 | -1 | -82 | -46 | — | — | |
| Operating Income | -252 | -191 | -115 | -55 | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 27 | 30 | 27 | 7 | — | — | |
| Net Income Before Taxes | -224 | -161 | -88 | -49 | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -224 | -161 | -88 | -49 | — | — | |
| Net Income From Continuing Operations | -224 | -161 | -88 | -49 | — | — | |
| Net Income | -224 | -161 | -88 | -49 | — | — | |
| EPS (Recurring) | -2.70 | -2.08 | -1.41 | -1.02 | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.70 | -2.08 | -1.41 | -1.02 | — | — | |
| EPS (Diluted) | -2.70 | -2.08 | -1.41 | -1.02 | — | — | |
| EBITDA | -220 | -160 | -88 | -49 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | 930.60 | 799.26 | 1,778.16 | — | — | — | |
| Gross Margin | -100.00 | -25.00 | -8,100.00 | — | — | — | |
| Operating Margin | -4,200.00 | -4,775.00 | -11,500.00 | — | — | — | |
| Net Margin | -3,733.33 | -4,025.00 | -8,800.00 | — | — | — | |
| Shares Outstanding | 88 | 77 | 62 | 67 | — | — | |
| Market Capitalization | 5,584 | 3,197 | 1,778 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| POST LEONARD E | Director | Oct 15 '26 | Sale | 62.06 | 1,000 | 62,065 | 0 | Oct 19 |
| POST LEONARD E | Director | Oct 15 '26 | Option Exercise | 0.60 | 1,000 | 600 | 1,000 | Oct 19 |
| POST LEONARD E | Director | Sep 15 '26 | Option Exercise | 0.60 | 1,000 | 600 | 1,000 | Sep 17 |
| POST LEONARD E | Director | Sep 15 '26 | Sale | 72.98 | 1,000 | 72,980 | 0 | Sep 17 |
| POST LEONARD E | Director | Aug 14 '26 | Option Exercise | 0.60 | 1,000 | 600 | 1,000 | Aug 18 |
| POST LEONARD E | Director | Aug 14 '26 | Sale | 74.54 | 1,000 | 74,540 | 0 | Aug 18 |
| POST LEONARD E | Director | Jul 15 '26 | Option Exercise | 0.60 | 1,000 | 600 | 1,000 | Jul 17 |
| POST LEONARD E | Director | Jul 15 '26 | Sale | 71.17 | 1,000 | 71,170 | 0 | Jul 17 |
| Mulay James | Director | Jul 10 '26 | Option Exercise | 26.63 | 24,165 | 643,514 | 24,165 | Jul 14 |
| Mulay James | Director | Jul 10 '26 | Sale | 75.16 | 24,165 | 1,816,241 | 0 | Jul 14 |
| Liu Brian Guan-Chyun | Director | Jun 25 '26 | Buy | 66.87 | 371,085 | 24,814,454 | 1,886,236 | Jun 29 |
| POST LEONARD E | Director | Jun 24 '26 | Option Exercise | 0.60 | 5,000 | 3,000 | 5,000 | Jun 25 |
| POST LEONARD E | Director | Jun 24 '26 | Sale | 70.00 | 5,000 | 350,000 | 0 | Jun 25 |
| POST LEONARD E | Director | Jun 22 '26 | Option Exercise | 0.60 | 5,000 | 3,000 | 5,000 | Jun 23 |
| POST LEONARD E | Director | Jun 22 '26 | Sale | 65.00 | 5,000 | 325,000 | 0 | Jun 23 |